During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderated by Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, the discussion centered around whether half-life extended peptides will eventually replace multispecific antibodies.

Links from this episode:  

PEGS Europe 
PEGS
Synthetic Design Lab
Genentech
Eli Lilly and Company
Lust for Life Science B.V. 



Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Cambridge Healthtech Institute. Innehållet i podden är skapat av Cambridge Healthtech Institute och inte av, eller tillsammans med, Poddtoppen.